Lonza News and Resources

Lonza, a global development and manufacturing partner for the pharmaceutical and biotech sectors, has joined CMAC to strengthen its service offering in particle technologies and drug product development. CMAC, based at the University of Strathclyde in Scotland, is a medicines

Ethris, a clinical-stage biotechnology company, has entered into a collaboration with Lonza, a global CDMO, to develop spray-dried, room-temperature stable mRNA-based vaccine candidates for mucosal delivery. The initiative aims to simplify vaccine distribution and administration, particularly for respiratory diseases. The focus

Lonza has announced that its new simplified and streamlined operating model is now in effect. The restructuring follows the company’s One Lonza vision, first introduced in December 2024, and aims to enhance scalability, improve execution, and strengthen its multimodality offering. The

Exogenus Therapeutics, a Portuguese biotech company, has partnered with Lonza to advance the development of Exo-101, its exosome-based lead candidate. The agreement focuses on establishing a Good Manufacturing Practice (GMP)-compliant process for clinical supply, leveraging Lonza’s expertise in exosome development and analytical

Lonza Capsules & Health Ingredients has announced the establishment of a Center of Applied Sustainability, aiming to integrate sustainability into product development and reduce its environmental footprint. The initiative aligns with Lonza’s near-term science-based emissions reduction targets, validated by the Science

Lonza has reported CHF 6.6 billion in sales for 2024, reflecting a slight decline of 0.2% at constant exchange rates (CER). The company achieved a CORE EBITDA of CHF 1.9 billion, maintaining a 29% margin, supported by strong demand for

Iconovo AB, an innovator in the development of inhalable drugs, has announced a collaboration with Lonza to develop a novel spray-dried formulation of an intranasal biologic aimed at treating obesity. This project marks the first step in Iconovo’s strategic initiative

Lonza, a global manufacturing partner for the pharmaceutical, biotech, and nutraceutical industries, has announced capacity expansions at its Rewari (India) and Suzhou (China) facilities. The additions include new manufacturing lines for hard gelatin capsules (HGCs), designed to support the production

Lonza has introduced its “One Lonza” strategy during its Investor Update 2024, focusing on the Contract Development and Manufacturing Organisation (CDMO) sector as its core business. The strategy includes a revised organizational structure aimed at streamlining operations, enhancing customer experience,

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has announced an extension of its service offerings to support the development of smart capsules for orally delivered biologic therapies. This expansion reflects the company’s commitment to addressing